| __timestamp | Dynavax Technologies Corporation | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 72471000 |
| Thursday, January 1, 2015 | 22180000 | 89204000 |
| Friday, January 1, 2016 | 37257000 | 106010000 |
| Sunday, January 1, 2017 | 27367000 | 137905000 |
| Monday, January 1, 2018 | 64770000 | 159888000 |
| Tuesday, January 1, 2019 | 74986000 | 158425000 |
| Wednesday, January 1, 2020 | 79256000 | 200677000 |
| Friday, January 1, 2021 | 100156000 | 304759000 |
| Saturday, January 1, 2022 | 131408000 | 377221000 |
| Sunday, January 1, 2023 | 152946000 | 336361000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Supernus Pharmaceuticals, Inc. and Dynavax Technologies Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Supernus consistently outpaced Dynavax, with SG&A expenses peaking at approximately 378% higher in 2022. This trend highlights Supernus's aggressive expansion and market penetration strategies. Meanwhile, Dynavax's SG&A expenses grew steadily, reflecting a more conservative approach, yet still achieving a notable 760% increase from 2014 to 2023. These figures underscore the diverse strategies employed by pharmaceutical companies to navigate market challenges and opportunities. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? GSK plc or Supernus Pharmaceuticals, Inc.
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
Grifols, S.A. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merus N.V. and Supernus Pharmaceuticals, Inc.
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation